Amylyx Pharmaceuticals Inc
AMLX
View Detailed Chart
13.980USD
+0.990+7.62%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
1.53BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+7.62%
5 Days
-2.17%
1 Month
+22.85%
6 Months
+70.70%
Year to Date
+15.73%
1 Year
+272.80%
View Detailed Chart
TradingKey Stock Score of Amylyx Pharmaceuticals Inc
Currency: USD Updated: 2026-02-06Key Insights
Amylyx Pharmaceuticals Inc's fundamentals are relatively weak, with industry-average ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 69 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 20.22.In the medium term, the stock price is expected to trend up.Despite a good stock market performance and strong technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Amylyx Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Amylyx Pharmaceuticals Inc Highlights
StrengthsRisks
Amylyx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on three investigational therapies across several neurodegenerative and endocrine diseases. Its lead investigational asset is avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist. Avexitide has been evaluated as a treatment for Post-Bariatric Hypoglycemia (PBH) and congenital HI, two indications characterized by hyperinsulinemic hypoglycemia. In addition to avexitide, it is advancing AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol in Wolfram syndrome and progressive supranuclear palsy (PSP), and AMX0114 in amyotrophic lateral sclerosis (ALS). AMX0035 is designed to mitigate neurodegeneration by targeting endoplasmic reticulum stress and mitochondrial dysfunction, two cellular processes central to neuronal cell death and neurodegeneration. AMX0114 is an investigational antisense oligonucleotide.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 293.03% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 87.37M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 87.37M.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Undervalued
The company’s latest PE is -7.80, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 113.87M shares, increasing 1.36% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 773.83K shares of this stock.
Analyst Rating
Based on
10
analysts
Strong Buy
Current Rating
20.222
Target Price
+55.68%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Amylyx Pharmaceuticals Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Amylyx Pharmaceuticals Inc Info
Amylyx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on three investigational therapies across several neurodegenerative and endocrine diseases. Its lead investigational asset is avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist. Avexitide has been evaluated as a treatment for Post-Bariatric Hypoglycemia (PBH) and congenital HI, two indications characterized by hyperinsulinemic hypoglycemia. In addition to avexitide, it is advancing AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol in Wolfram syndrome and progressive supranuclear palsy (PSP), and AMX0114 in amyotrophic lateral sclerosis (ALS). AMX0035 is designed to mitigate neurodegeneration by targeting endoplasmic reticulum stress and mitochondrial dysfunction, two cellular processes central to neuronal cell death and neurodegeneration. AMX0114 is an investigational antisense oligonucleotide.
Ticker SymbolAMLX
CompanyAmylyx Pharmaceuticals Inc
CEOKlee (Justin)
Websitehttps://www.amylyx.com/
Related Instruments
+3.66%
+3.17%
+0.93%
+1.99%
+1.78%
+1.60%
-0.95%
+4.49%
+2.10%
+10.00%
+2.72%
+4.15%
+1.81%
+4.17%
+0.72%
+1.06%
+2.46%
0.00%
+0.53%
+0.56%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
68942.900
-1027.230 (-1.47%)
282.580
+22.390 (+8.61%)
2038.760
-12.970 (-0.63%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
